BarbaraJGitlitzMD

Oncology • Los Angeles, CA

Associate Clinical Professor of Medicine, USC-Keck School of Medicine

Join to view full profile

Dr. Gitlitz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Gitlitz's full profile

Already have an account?

Office
1441 Eastlake Ave
Nor 8302e
Los Angeles, CA 90089
Phone+1 323-865-3105
Is this information wrong?

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1992 - 1995
Cedars-Sinai Medical CenterResidency, Internal Medicine, 1990 - 1992
UCLA David Geffen School of Medicine/UCLA Medical CenterInternship, Internal Medicine, 1989 - 1990
Stony Brook University Health Sciences Center School of MedicineClass of 1989

Certifications & Licensure

CA State Medical License 1990 - 2024

Awards, Honors, & Recognition

Top Doctors:LA Area Castle Connolly, 2013
Top Doctors:Southern California Castle Connolly, 2012
Super Doctor SuperDoctors.com

Clinical Trials

Vaccine Therapy in Treating Patients With Advanced Kidney Cancer Start of enrollment: 1997 Jun 01
Completed
Phase 1
Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2005 Jul 01
Completed
Phase 2
Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2004 Sep 01
Terminated
Phase 2
Cancer Treatment Followed by Surgery for Early Stage Non-small Cell Lung Cancer Start of enrollment: 2006 Apr 01
Withdrawn
Phase 1, Phase 2
E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2006 Nov 01
Completed
Phase 2
A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma Start of enrollment: 2008 Apr 01
Withdrawn
Phase 1, Phase 2
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma Start of enrollment: 2010 Mar 15
Active, not recruiting
Phase 1, Phase 2
Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer Start of enrollment: 2010 Sep 09
Completed
Phase 1, Phase 2
Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network Start of enrollment: 2010 Nov 01
Terminated
Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors Start of enrollment: 2012 Jul 24
Completed
Phase 1
Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery Start of enrollment: 2012 Aug 20
Completed
Phase 2
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Oct 14
Completed
Phase 2
Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer Start of enrollment: 2013 May 01
Terminated
Phase 2
Molecular Signatures of Relapse in Tissue Samples From Patients With Small Cell Lung Cancer Who Are Receiving Cisplatin and Etoposide Start of enrollment: 2014 Aug 22
Withdrawn
Join now to see all

Publications & Presentations

PubMed

7 citations
The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung Cancer.
Barbara J. Gitlitz, Silvia Novello, Tiziana Vavalà, Marisa A. Bittoni, Alicia Sable-Hunt, Dean Pavlick, Robert Hsu, S. Lani Park, Matthew Cooke, Amy Moore, Alexa B. Sc...> ;JTO Clinical and Research Reports. 2021 Jul 1
17 citations
Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Dise...
Karen L. Reckamp, Paul Frankel, Nora Ruel, Philip C. Mack, Barbara J. Gitlitz, Tianhong Li, Marianna Koczywas, Shirish M. Gadgeel, Mihaela C. Cristea, Chandra P. Belan...> ;Frontiers in Oncology. 2019 Mar 11
67 citations
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Rand...
Robert L. Ferris, Nabil F. Saba, Barbara J. Gitlitz, Robert I. Haddad, Ammar Sukari, Prakash Neupane, John C. Morris, Krzysztof Misiukiewicz, Julie E. Bauman, Moon Fen...> ;JAMA Oncology. 2018 Nov 1
6 citations
A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors.
Stephen V. Liu, Susan Groshen, Karen Kelly, Karen L. Reckamp, Chandra P. Belani, Timothy W. Synold, Amir Goldkorn, Barbara J. Gitlitz, Mihaela C. Cristea, I-Yeh Gong, ...> ;Cancer Chemotherapy and Pharmacology. 2018 Aug 20
117 citations
Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
Leora Horn, Jeffrey R. Infante, Karen L. Reckamp, George R. Blumenschein, Ticiana A. Leal, Saiama N. Waqar, Barbara J. Gitlitz, Rachel E. Sanborn, Jennifer G. Whisenan...> ;Clinical Cancer Research. 2018 Jun 15
262 citations
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-97...
Brigette B.Y. Ma, Wan-Teck Lim, Boon Cher Goh, Edwin P. Hui, Kwok Wai Lo, Adam Pettinger, Nathan R. Foster, Jonathan W. Riess, Mark Agulnik, Alex Y. Chang, Akhil Chopr...> ;Journal of Clinical Oncology. 2018 Mar 27
3 citations
Publisher Correction: Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Nature Communications. 2018 Jan 8
33 citations
Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Nature Communications. 2017 Nov 27
53 citations
Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without pri...
Sai-Hong Ignatius Ou, Thomas K. Lee, Lauren Young, Maria Y. Fernandez-Rocha, Dean Pavlick, Alexa B. Schrock, Viola W. Zhu, Jeffrey C. Milliken, Siraj M. Ali, Barbara J...> ;Lung Cancer. 2017 Apr 1
63 citations
HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afa...
Sai-Hong Ignatius Ou, Alexa B. Schrock, Eduard V. Bocharov, Samuel J. Klempner, Carolina Kawamura Haddad, Gary Steinecker, Melissa Lynne Johnson, Barbara J. Gitlitz, J...> ;Journal of Thoracic Oncology. 2017 Mar 1
P1.49 (also presented as PD1.05): The Genomics of Young Emergent Lung Cancer: Track: Advanced NSCLC.
Barbara J. Gitlitz, Bonnie J. Addario, Alicia L. Sable-Hunt, Silvia Novello, Tiziana Vavalà, Ruthia Chen, Marisa A. Bittoni, S.L. Park, Mark Byron Jennings, Geoffrey R...> ;Journal of Thoracic Oncology. 2016 Oct 1
1 citations
PD1.05 (also presented as P1.49): The Genomics of Young Emergent Lung Cancer
Barbara J. Gitlitz, Bonnie J. Addario, Alicia L. Sable-Hunt, Silvia Novello, Tiziana Vavalà, Ruthia Chen, Marisa A. Bittoni, S. Lani Park, Mark Byron Jennings, Geoffre...> ;Journal of Thoracic Oncology. 2016 Oct 1
81 citations
EGFR fusions as novel therapeutic targets in lung cancer
Kartik Konduri, Jean-Nicolas Gallant, Young Kwang Chae, Francis J. Giles, Barbara J. Gitlitz, Kyle Gowen, Eiki Ichihara, Taofeek K. Owonikoko, Vijay Peddareddigari, Su...> ;Cancer Discovery. 2016 Jun 1
65 citations
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer†
Khozin, S., Corey A. Carter, Arun Rajan, Corrine Keen, Eva Szabo, Sean Khozin, Anish Thomas, Christina Brzezniak, Udayan Guha, L. A. Doyle, Seth M. Steinberg, Liqiang ...> ;Annals of Oncology. 2016 Apr 1
11 citations
Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWO...
Primo N. Lara, James Moon, Mary W. Redman, Thomas J. Semrad, Karen Kelly, Jeffrey Warren Allen, Barbara J. Gitlitz, Philip C. Mack, David R. Gandara> ;Clinical Lung Cancer. 2016 Mar 1
51 citations
Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Who Previously Progressed on Erlotinib
Primo N. Lara, Jeff Longmate, Philip C. Mack, Karen Kelly, Mark A. Socinski, Ravi Salgia, Barbara J. Gitlitz, Tianhong Li, Marianna Koczywas, Karen L. Reckamp, David R...> ;Clinical Cancer Research. 2015 Oct 1
63 citations
I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sen...
Sai-Hong Ignatius Ou, Joel R. Greenbowe, Ziad U. Khan, Michele C. Azada, Jeffrey S. Ross, Phil J. Stevens, Siraj M. Ali, Vincent A. Miller, Barbara J. Gitlitz> ;Lung Cancer. 2015 May 1
20 citations
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncolog...
Primo N. Lara, James Moon, Mary W. Redman, Thomas J. Semrad, Karen Kelly, Jeffrey Warren Allen, Barbara J. Gitlitz, Philip C. Mack, David R. Gandara> ;Journal of Thoracic Oncology. 2015 Jan 1
4 citations
Eribulin: a new-generation antimicrotubule agent in lung cancer therapy.
Eddie Thara, Barbara J. Gitlitz> ;Future Oncology. 2014 Nov 11
8 citations
Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors
Caroline I. Piatek, Grace L. Raja, Lingyun Ji, Barbara J. Gitlitz, Tanya B. Dorff, David I. Quinn, James C. Hu, Anthony B. El-Khoueiry, Huyen Q. Pham, Lynda D. Roman, ...> ;Cancer Chemotherapy and Pharmacology. 2014 Nov 6
25 citations
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lu...
Barbara J. Gitlitz, Eric Bernstein, Edgardo S. Santos, Greg Otterson, Ginger L. Milne, Mary Syto, Francis Burrows, Sara Zaknoen> ;Journal of Thoracic Oncology. 2014 Apr 1
103 citations
Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma.
Julie Ann Sosa, Rossella Elisei, Barbara Jarzab, Jai Balkissoon, Shiao Ping Lu, Chandrasekhar Bal, Shanthi Marur, Ann Wild Gramza, Rami Ben Yosef, Barbara J. Gitlitz, ...> ;Thyroid. 2014 Feb 11
17 citations
Pertuzumab and Erlotinib in Patients With Relapsed Non-Small Cell Lung Cancer: A Phase II Study Using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomo...
Brett G.M. Hughes, Linda Mileshkin, Peter Townley, Barbara J. Gitlitz, Keith D. Eaton, Paul Mitchell, Rodney J. Hicks, Katie Wood, Lucas Amler, Bernard M. Fine, David ...> ;The Oncologist. 2014 Feb 1
26 citations
Epigenetic Therapy in Lung Cancer
Stephen V. Liu, Muller Fabbri, Barbara J. Gitlitz, Ite A. Laird-Offringa> ;Frontiers in Oncology. 2013 May 30
45 citations
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
Nicholas P. Campbell, Rangesh Kunnavakkam, Natasha B. Leighl, Mark Vincent, David R. Gandara, Marianna Koczywas, Barbara J. Gitlitz, Edem Agamah, Sachdev P. Thomas, Wa...> ;Lung Cancer. 2012 Oct 1
Join now to see all

Journal Articles

Transcribed Ultraconserved Region 339 Promotes Carcinogenesis by Modulating Tumor Suppressor microRNAs
Barbara Gitlitz, MD, Nature

Press Mentions

New Study Seeks Origins of Young Lung CancerFebruary 23rd, 2021
Distinct Genomic Differences Evident in Younger Patients with Lung CancerFebruary 5th, 2016
Lung Cancer Research Shows Distinct Genomic Differences in Younger PatientsJanuary 6th, 2016
Join now to see all